Date:3/5/2009

(6,035) 10,962 4,927 ------------------------------------------------------------------------- Other income (expenses): Foreign exchange gain (loss) 173 (173) h - Investment and other income 511 155 i 666 Interest expense on long-term debt (12,774) 558 j (12,216) Write-down and other deferred financing charges - - - Write-down / loss on redemption of investments - - - Write-down of assets held for sale - - - Write-down of goodwill - - - ------------------------------------------------------------------------- ------------------------------------------------------------------------- (12,090) 540 (11,550) ------------------------------------------------------------------------- ------------------------------------------------------------------------- (Loss) income from continuing operations before income taxes (18,125) 11,502 (6,623) Income tax (recovery) expense 6,788 3,626 o 10,414 ------------------------------------------------------------------------- ------------------------------------------------------------------------- (Loss) income from continuing operations (24,913) 7,876 (17,037) Net loss from discontinued operations, net of income taxes (2,946) 2,946 - ------------------------------------------------------------------------- Net (loss) income for the period $ (27,859) $ 10,822 $ (17,037) ------------------------------------------------------------------------- Basic
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study